16 Jul , 2025 By : Debdeep Gupta
Zydus Lifesciences share price up marginally in the opening trade on July 16 following the company received USFDA approval for nonsteroidal anti-inflammatory drug.
At 09:19am, Zydus Lifesciences was quoting at Rs 973.55, up Rs 6.40, or 0.66 percent, on the BSE.
".... has received final approval from the United States Food and Drug Administration (USFDA) for Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg," company said in its release.
Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) to reduce hormones that cause inflammation and pain in the body.
It is used to treat pain or inflammation caused by many conditions such as arthritis, ankylosing spondylitis, and menstrual pain, it added.
It is also used to treat juvenile rheumatoid arthritis in children who are at least 2 years old.
The capsules will be produced at company's, Ahmedabad facility.
The group now has 428 approvals and has so far filed 492 ANDAs since the commencement of the filing process in FY 2003-04.
In the month of June, the company received two observations from US Food and Drug Administration (USFDA) post inspection conducted between June 9-18 at its oncology injectable site situated at SEZ 1, near Matoda, Ahmedabad.
0 Comment